Norman Michael Greenberg
Profile
Norman Michael Greenberg is currently a Director at Mongoose Bio, Inc. He was previously the Chief Scientific Officer at Atreca, Inc. from 2016 to 2021, Vice President-Global Research at Medimmune, Inc. from 2011 to 2014, Senior Vice President-Translational Medicine at Checkmate Pharmaceuticals, Inc. from 2015 to 2016, and President & Chief Executive Officer at NMG Scientific Consulting USA from 2014 to 2016.
He also held positions as a Senior Director-Research at Pfizer Inc. from 2009 to 2011 and an Associate Professor at Baylor College of Medicine from 1998 to 2003.
Dr. Greenberg is a doctorate graduate from the University of British Columbia and an undergraduate graduate from the University of Toronto.
Norman Michael Greenberg active positions
| Companies | Position | Start |
|---|
Former positions of Norman Michael Greenberg
| Companies | Position | End |
|---|---|---|
| ATRECA, INC. | Chief Tech/Sci/R&D Officer | 2021-03-30 |
| CHECKMATE PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2016-04-30 |
| NMG Scientific Consulting USA | Chief Executive Officer | 2016-04-30 |
| Medimmune, Inc. | Chief Tech/Sci/R&D Officer | 2014-04-30 |
| PFIZER, INC. | Chief Tech/Sci/R&D Officer | 2011-06-30 |
Training of Norman Michael Greenberg
| University of Toronto | Undergraduate Degree |
| University of British Columbia | Doctorate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ATRECA, INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Checkmate Pharmaceuticals, Inc.
 Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
| Medimmune, Inc. | Health Technology |
Fred Hutchinson Cancer Research Center
 Fred Hutchinson Cancer Research Center Miscellaneous Commercial ServicesCommercial Services Fred Hutchinson Cancer Research Center is a non-profit organization which provides research and testing services. The company was founded in 1965 and is headquartered in Seattle, WA. | Commercial Services |
| NMG Scientific Consulting USA |
- Stock Market
- Insiders
- Norman Michael Greenberg
